Jinteli
Pronunciation: Not established in the supplied research notes..
- Generic name
- norethindrone acetate and ethinyl estradiol
- Brand names
- Jinteli
- Drug class
- Continuous combined menopausal hormone therapy
- Form
- White tablet containing norethindrone acetate 1 mg and ethinyl estradiol 5 mcg
- Route
- Oral
- Legal status
- Not established in the supplied research notes.
Availability and supply rules vary by country
Trade names by country: United States
Australia: · Full directory
What norethindrone acetate and ethinyl estradiol is and how it works
Jinteli is a continuous combined menopausal hormone therapy tablet containing norethindrone acetate and ethinyl estradiol. It is used for certain menopause-related indications in postmenopausal women with a uterus. (1)
The norethindrone acetate component is included to reduce the endometrial cancer risk associated with unopposed estrogen in women who have a uterus. Treatment should use the lowest effective dose for the shortest duration consistent with treatment goals, with periodic reassessment of the need for continued treatment.
Mechanism of action: how norethindrone acetate and ethinyl estradiol works
Jinteli is a continuous combined menopausal hormone therapy containing norethindrone acetate and ethinyl estradiol. In women with a uterus, the progestin component is included to reduce the endometrial cancer risk associated with unopposed estrogen. (1)
What norethindrone acetate and ethinyl estradiol is used for
Moderate to severe vasomotor symptoms due to menopause
Jinteli is indicated for treatment of moderate to severe vasomotor symptoms, including hot flashes and night sweats, due to menopause. (1)
Prevention of postmenopausal osteoporosis
Jinteli is indicated for prevention of postmenopausal osteoporosis in women with a uterus. (1)
Before taking norethindrone acetate and ethinyl estradiol
Do not take / not appropriate for
- Jinteli is contraindicated with undiagnosed abnormal vaginal bleeding. (all use) (1)
- Jinteli is contraindicated with known, suspected, or a history of breast cancer; or with known or suspected estrogen-dependent neoplasia. (all use) (1)
- Jinteli is contraindicated with active deep vein thrombosis or pulmonary embolism, a history of these conditions, active or recent arterial thromboembolic disease such as stroke or myocardial infarction, or known thrombophilic disorders. (all use) (1)
- Jinteli is contraindicated with known liver impairment or disease, known or suspected pregnancy, or hypersensitivity to any product component. (all use) (1)
Tell your clinician about
- Any abnormal vaginal bleeding.
- Any history of breast cancer, estrogen-dependent neoplasia, deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, thrombophilic disorders, or liver impairment or disease.
- All medicines and supplements, including St. John's Wort, rifampin, carbamazepine, other anticonvulsants, ketoconazole, ritonavir, erythromycin, and lamotrigine.
- Pregnancy, a possible pregnancy, plans for pregnancy, breastfeeding, or plans to breastfeed.
How to take norethindrone acetate and ethinyl estradiol
- The labeled dose is one Jinteli tablet, containing norethindrone acetate 1 mg and ethinyl estradiol 5 mcg, taken by mouth once daily.
- Jinteli is taken continuously, not cyclically, for either labeled indication.
- Use the lowest effective dose for the shortest duration consistent with treatment goals. The prescriber should periodically reassess the need for continued treatment.
- Do not change the prescribed dose or schedule without direction from the prescriber.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
Missed-dose instructions were not extracted from the supplied research notes. Contact the prescribing clinician or pharmacist for advice; do not take an extra dose unless they direct it.
Overdose
Overdose management information was not extracted from the supplied research notes. If more than the prescribed amount may have been taken, contact a clinician, pharmacist, poison-information service, or emergency service as appropriate. (1)
Side effects
In clinical trials, adverse reactions reported in at least 5% of participants included headache, abdominal pain, breast pain or tenderness, and generalized edema.
Headache
What to notice: Headache.
What to do: Discuss persistent or troublesome symptoms with the prescribing clinician. (1)
Abdominal pain
What to notice: Abdominal pain.
What to do: Discuss persistent or troublesome symptoms with the prescribing clinician. (1)
Breast pain or tenderness
What to notice: Breast pain or tenderness.
What to do: Discuss persistent or troublesome symptoms with the prescribing clinician. (1)
Generalized edema
What to notice: Generalized swelling.
What to do: Discuss persistent or troublesome symptoms with the prescribing clinician. (1)
Abnormal vaginal bleeding
What to notice: Any vaginal bleeding that is abnormal or unexplained.
What to do: Contact the prescribing clinician promptly for assessment and monitoring. (1)
Possible gallbladder disease
What to notice: Specific symptoms were not extracted in the supplied research notes.
What to do: Seek prompt medical assessment for suspected gallbladder disease. (1)
Serious warnings
Venous thromboembolism — emergency
Symptoms: Deep vein thrombosis or pulmonary embolism is suspected or diagnosed. Specific symptom descriptions were not extracted in the supplied research notes.
Action: Seek urgent medical assessment. Estrogen-plus-progestin therapy is associated with an approximately two-fold higher rate of venous thromboembolism than placebo; the clinician assessing the event must direct treatment decisions. (1)
Stroke or myocardial infarction — emergency
Symptoms: Possible stroke or myocardial infarction. Specific symptom descriptions were not extracted in the supplied research notes.
Action: Seek emergency medical care. Combined estrogen-progestin therapy increased stroke risk in Women's Health Initiative trial data, and myocardial infarction risk was higher in the first year of use in trial data. (1)
Breast cancer — serious
Symptoms: Specific symptoms were not extracted in the supplied research notes.
Action: Discuss breast cancer risk and any concerning findings with the prescribing clinician. The Women's Health Initiative study reported an increased risk of invasive breast cancer with combined estrogen-progestin therapy. (1)
Endometrial cancer risk and abnormal bleeding — serious
Symptoms: Abnormal vaginal bleeding.
Action: Contact the prescribing clinician promptly for evaluation. Unopposed estrogen significantly increases endometrial cancer risk in women with a uterus; adding a progestin is intended to reduce this risk, but abnormal bleeding requires monitoring. (1)
Probable dementia risk in women aged 65 years or older — serious
Symptoms: Specific symptoms were not extracted in the supplied research notes.
Action: Discuss the risk and the ongoing need for treatment with the prescribing clinician. Combined estrogen-progestin therapy should not be used to prevent dementia. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| CYP3A4 inducers | CYP3A4 inducers, including St. John's Wort, rifampin, carbamazepine, and other anticonvulsants, may lower circulating hormone levels and reduce effectiveness. Breakthrough bleeding may occur. | Give the prescriber and pharmacist a complete list of medicines and supplements so they can assess interactions. (1) |
| CYP3A4 inhibitors | CYP3A4 inhibitors, including ketoconazole, ritonavir, and erythromycin, may increase hormone exposure. | Give the prescriber and pharmacist a complete list of medicines and supplements so they can assess interactions. (1) |
| Lamotrigine | Concomitant use may reduce lamotrigine plasma levels and potentially reduce seizure control in people with epilepsy. | A clinician may need to adjust lamotrigine under clinical supervision. Do not alter lamotrigine treatment without prescriber direction. (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Postmenopausal women
Jinteli is a menopausal hormone therapy product for postmenopausal women. Its labeled indications include vasomotor symptom treatment and prevention of postmenopausal osteoporosis in women with a uterus. (1)
Pregnancy
Jinteli is contraindicated in known or suspected pregnancy and is not indicated for use during pregnancy. If pregnancy occurs or is suspected, seek prompt advice from the prescriber, who should direct treatment decisions. (1)
Breastfeeding
Estrogens are present in breast milk and may reduce milk production or quality. Use during breastfeeding requires a prescriber-led risk-benefit assessment. (1)
Renal impairment
Specific renal-impairment dosing guidance was not extracted from the supplied research notes. (1)
Monitoring
Before starting
- Confirm the labeled indication and postmenopausal status.
- Assess for contraindications, including abnormal vaginal bleeding, breast cancer, estrogen-dependent neoplasia, thromboembolic disease, arterial thromboembolic disease, liver impairment or disease, thrombophilic disorders, pregnancy, and hypersensitivity.
- Review all medicines and supplements for interaction risks, including CYP3A4 inducers, CYP3A4 inhibitors, and lamotrigine.
- Discuss breast cancer, endometrial cancer, cardiovascular, venous thromboembolism, stroke, myocardial infarction, gallbladder disease, and probable dementia risks.
During treatment
- Periodically reassess the need for continued treatment and whether the lowest effective dose is being used for the shortest duration consistent with treatment goals.
- Monitor and evaluate abnormal vaginal bleeding.
- Assess for possible venous thromboembolism, stroke, myocardial infarction, breast cancer, gallbladder disease, and other adverse reactions.
- Review concomitant medicines and supplements for changes that may affect hormone exposure or lamotrigine levels.
Storage
Storage instructions were not extracted from the supplied research notes. Follow the product packaging and pharmacist's instructions.
Professional information
Clinician-facing context only. Consult the current US product label and assess indication, contraindications, risks, interactions, and ongoing need for therapy.
United States
Indication: Moderate to severe vasomotor symptoms due to menopause; prevention of postmenopausal osteoporosis in women with a uterus
Dose summary: One tablet containing norethindrone acetate 1 mg and ethinyl estradiol 5 mcg orally once daily, continuously, for either labeled indication. Use the lowest effective dose for the shortest duration consistent with treatment goals and periodically reassess continued need.
Renal context: No specific renal-impairment dosing guidance was extracted from the supplied research notes. (1)
Hepatic guidance
Jinteli is contraindicated in known liver impairment or disease.
Overdose note
Overdose-management details were not extracted from the supplied research notes. (1)
Frequently asked questions
Is Jinteli a birth-control pill?
No. Although it contains hormone classes also used in some contraceptives, Jinteli is menopausal hormone therapy. It is not indicated or effective for pregnancy prevention. (1)
How is Jinteli taken?
The labeled dose is one tablet by mouth once daily, taken continuously rather than cyclically. Follow the prescriber's instructions and do not change the schedule without their direction. (1)
Why does Jinteli contain norethindrone acetate as well as estrogen?
For women with a uterus, the progestin component is included to reduce the endometrial cancer risk that unopposed estrogen would otherwise cause. (1)
Can Jinteli be used to prevent heart disease or dementia?
No. Estrogen-progestin therapy should not be used for prevention of cardiovascular disease or dementia. (1)
What is the mechanism of action of norethindrone acetate and ethinyl estradiol?
Jinteli is a continuous combined menopausal hormone therapy containing norethindrone acetate and ethinyl estradiol. In women with a uterus, the progestin component is included to reduce the endometrial cancer risk associated with unopposed estrogen. (1)
What is the generic name of Jinteli?
The generic name is norethindrone acetate and ethinyl estradiol. It is sold under brand names including Jinteli. (1)
What class of drug is norethindrone acetate and ethinyl estradiol?
Jinteli is classed as: Continuous combined menopausal hormone therapy. (1)
References
- JINTELI (norethindrone acetate and ethinyl estradiol) tablet — prescribing informationU.S. Food and Drug Administration (via DailyMed) · United States · accessed 2026-08-05 · source 1
- NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE KIT [AMNEAL PHARMACEUTICALS LLC] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 2
- Aranelle — FDA approval record (Drugs@FDA ANDA076783)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 3
Brand names by country
Single-ingredient norethindrone acetate and ethinyl estradiol names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Junel 21 Day
- Fyavolv
- LUIZZA 1/20
- Loestrin 21 Day
- Aurovela 1/20
- Junel FE
- Jinteli
- Hailey 1.5/30
- Nortrel 21 Day